May 17th 2010 - Edison Investment Research today published a report on MedicX Fund (MXF.L, LSE:MXF, LON:MXF) entitled "Improved Growth Outlook". In summary, the report says:
The recent fund-raising provided capital to accelerate the pace of acquisitions, which should in turn enhance earnings, dividends and NAV/share. Opportunities to invest the funds are provided by the fund's development pipeline, while access to fixed-rate debt and recent revisions to the management fee structure will translate greater scale into faster earnings growth and dividend cover. A highly stable asset class should benefit from capital growth in line with improving fundamentals and recovery in UK commercial property values. We will review forecasts post interim results on 26 May.
Edison Investment Research is a leading international investment research company. It has won industry recognition, with awards both in the UK and internationally. The team of 95 includes over 60 analysts supported by a department of supervisory analysts, editors and assistants. Edison writes on more than 400 companies across every sector and works directly with corporates, fund managers, investment banks, brokers and other advisers. Edison’s research is read by institutional investors, alternative funds and wealth managers in more than 100 countries. Edison, founded in 2003, has offices in London, New York and Sydney and is authorised and regulated by the Financial Services Authority (www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584). more »